 Good day everyone and welcome to this Investor Intel interview. My name is Mario Jolé. It's a pleasure to always see you every day. Today we have the pleasure to have with us Mr. Mike Drewain from MidEx Health Development Company. Good day Mike and welcome to the show. Hey Mario, nice to see you again my friend. Thank you sir. Mike, first question for you. Can you walk us through the latest development that MidEx had just recently? So what we've done Mario is our shareholders, we listen very carefully to them and their whole conversation with us has been show us the revenue, let's see the traction. So as of November 17th of shareholders go back they'll notice a flurry of releases showing them exactly that. So what we're doing now with our model to make it work more efficiently for everybody is we're putting note a lot more of the you know the traction we're getting on the revenue side, we're explaining it and one little caveat to it. A lot of the stuff we've done in the past we went back and reviewed and we're doing these contracts. COVID gave us a chance to reflect on how we could be better at communicating to our shareholders one and secondly how can we be more efficient in terms of how we get our customers up and running in that. So we spent a lot of time on that part of the operational efficiency. So now what we do is we go into a partnership, we do a pilot that's paid for. I want to be really clear about that. So we do a pilot, we run it anywhere from 60 to 90 days and what that does is it allows both the partner and us to understand each other's business model and then at the end of it it turns into a commercial contract which gives us an idea of what the partner is like so we both have to measure each other's end points and say okay you delivered what you said, we delivered what we said, this will make a good commercial arrangement. So it stops us doing those sort of engagements with like big blue sky in them and then all of a sudden we run into some problems and it looks like we're not doing our job correctly. So we wanted to get that corrected and that's how we're doing it now. So if you go back into from I think in November 17th somewhere around there there's a host of announcements we've done Mario and all of those are all pilot driven, paid for and now we're starting to turn some of those into commercial contracts and I think people will start to see a lot more of those coming and they'll be able to track those on our website now. Mike can you talk about Medicare? Right so Medicare was a deal we just recently did and in the Medicare transaction this was this was the first physician-based transaction we did so now we have sort of three channels, we have the pharmacy channel, we have the medical clinic channel and now this was the first one we did direct physician-owned so this was a physician she has a small community of actually 5,000 patient roster but she services highly Arabic community and this was an excellent opportunity for us to go into an underserved community be able to allow her to gain access to the dermatological community services that are there and it's also directly connected to a pharmacy so with the addition of the HD camera that we have this allows her to take any other kind of skin ailments inflammatory skin diseases and then take any kinds of the treatments that are pharmacology treatments into the pharmacy so it's a unique model for us and these kind of things that they're part of the three-legged stool we have you know the medical clinics the pharmacies direct and then the physician paid so yeah this is an interesting one we're pretty happy about that we got lots more of those on the pipe coming. Can wait to see more development on it Mike can you also talk about Brazil what's going on? So Brazil was a classic example of what I was talking about earlier we went into the Brazil market we still think we have a very excellent partner down in Brazil COVID hit Brazil very hard and the problem with that was I mean it was really under shutdown anybody who's watching the news knows that we're just coming out of that malaise of Brazil we've been nothing's gone in terms of problematic with Brazil in terms of other than we couldn't get into the to the ease of access locations so we're now starting to reboot that now that the COVID has simmered down enough that allows us to do it we've been very active on the training program with the hospitals we've been going into some of the newer hospitals we've done a lot of training down there so I expect in the next couple quarters we'll see a lot more business out of Brazil so Brazil I think everybody's worried about that you know that was a false flag but it isn't it's just a matter we'll we'll start to manage that a lot more aggressively now that it's open back up in the economy Mike my last question for you basically what can we expect for shareholders of Medex in 2022 like some yes rising sales can we start to see think about seeing maybe a positive a bit dubbed by the end of the quarter four of that 2022 yeah so we've become one of the things is people have been very patient or feel that we haven't delivered on the traction side and I think that's a very that's very authentic I think what we're going to see this year is our team is deeply focused we have made a commitment to get 158 scopes owed into the first quarter if we do that that starts to turns our numbers towards cash flow positive and that's really good and we're on track for those numbers to come in and so this year we've got a target number with our scopes to get us into highly profitable range and I will say with the mo use developing the commercialized contracts and the commitments to that I think everybody will see a lot of revenue traction and I think the way we're going to measure that now to help people out with that Mario is we're just building the back end of the site right now but people will be able to go on to a map that we have under the get scan part on our website see the number of locations populate we'll start to put how many devices that we're putting into each market so we'll put down a tabulation poll that'll say you know this quarter we opened up 158 scopes that way people know we're on track and then we'll show the number of e-consults we've conducted and we make about $15 minimum on those e-consults so people will be able to do the math and kind of get a nine on the revenue trend so I think we'll be far more transparent this year that's one of the things our shareholders have demanded will be a lot more transparent so I think we're going to have a year of lots of traction and lots of revenue finally but finally so I think everybody will be pretty happy about that hey thank you very much Mike was very nice to have you today on investor intel interview just want to remind you medx mdx on tsx venture and thank you very much to all of you thank you thank you